Organization | University of Burgos

University of Burgos Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4

Organization Overview

First Clinical Trial

2011

NCT01744249

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2024

Timeline

NOW

Now

Alternative names

Complejo asistencial Universitario de Burgos | Esther Cubo | Hospital Universitario de Burgos | Hospital Universitario de Burgos, Spain | Universidad de Burgos | University of Burgos

Active Ingredients

Drugs in Phase 4 Trials (1)

ringer's lactate (1 trial)

Drugs in Phase 3 Trials (3)

adalimumab (humira) (1 trial)

sweet vernal, orchard, perennial rye, timothy, and kentucky blue grass mixed pollens allergen extract (Oralair) (1 trial)

Drugs in Phase 2 Trials (2)

axitinib (inlyta) (1 trial)

octreotide (sandostatin) (1 trial)

Drugs in Other Trials (1)

creatine (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Crohn Disease (Phase 3)

Neuroendocrine Tumors (Phase 2)

Overview

Highest Phase: Phase 4
# of Trials: 5
# of Trial APIs: 7